Suzhou HepaThera Biotech Co., Ltd.
4 clinical trials · Sponsor
◉ Watch Suzhou HepaThera Biotech Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection (NCT07245953) | Suzhou HepaThera Biotech Co., Ltd. | 2025-11-05 |
| A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection (NCT07183306) | Suzhou HepaThera Biotech Co., Ltd. | 2024-12-30 |
| Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection) (NCT06744686) | Suzhou HepaThera Biotech Co., Ltd. | 2023-06-12 |
| This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (NCT06746311) | Suzhou HepaThera Biotech Co., Ltd. | 2022-11-22 |
Track Suzhou HepaThera Biotech Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.